GeneDx (NASDAQ:WGS) Trading Up 5.6%

GeneDx Holdings Corp. (NASDAQ:WGS) traded up 5.6% on Monday . The company traded as high as $27.60 and last traded at $27.60. 145,791 shares changed hands during trading, a decline of 62% from the average session volume of 385,836 shares. The stock had previously closed at $26.14.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. TD Cowen upped their price objective on shares of GeneDx from $14.00 to $24.00 and gave the company a “buy” rating in a research note on Tuesday, April 30th. Jefferies Financial Group assumed coverage on GeneDx in a research note on Monday, June 3rd. They set a “hold” rating and a $21.00 price objective on the stock. BTIG Research boosted their target price on GeneDx from $19.00 to $35.00 and gave the company a “buy” rating in a research note on Wednesday, June 26th. Finally, The Goldman Sachs Group raised their price target on GeneDx to $11.00 and gave the stock a “neutral” rating in a research report on Monday, April 15th.

GeneDx Stock Performance

The business’s 50-day simple moving average is $22.56 and its 200-day simple moving average is $12.06. The company has a debt-to-equity ratio of 0.25, a current ratio of 3.22 and a quick ratio of 2.99.

GeneDx (NASDAQ:WGS) last released its quarterly earnings data on Monday, April 29th. The company reported ($0.33) earnings per share for the quarter, topping the consensus estimate of ($0.68) by $0.35. GeneDx had a negative return on equity of 36.23% and a negative net margin of 60.86%. The business had revenue of $62.42 million during the quarter, compared to analysts’ expectations of $49.80 million. As a group, equities analysts predict that GeneDx Holdings Corp. will post -0.92 EPS for the current year.

Insider Buying and Selling at GeneDx

In related news, CEO Katherine Stueland sold 6,325 shares of the business’s stock in a transaction dated Monday, April 29th. The shares were sold at an average price of $11.04, for a total transaction of $69,828.00. Following the transaction, the chief executive officer now owns 75,869 shares in the company, valued at $837,593.76. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other news, CFO Kevin Feeley sold 2,646 shares of the business’s stock in a transaction that occurred on Monday, June 17th. The stock was sold at an average price of $28.31, for a total value of $74,908.26. Following the sale, the chief financial officer now directly owns 37,409 shares of the company’s stock, valued at approximately $1,059,048.79. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Katherine Stueland sold 6,325 shares of the firm’s stock in a transaction that occurred on Monday, April 29th. The shares were sold at an average price of $11.04, for a total value of $69,828.00. Following the transaction, the chief executive officer now directly owns 75,869 shares of the company’s stock, valued at approximately $837,593.76. The disclosure for this sale can be found here. In the last ninety days, insiders have purchased 175,804 shares of company stock valued at $3,771,670 and have sold 21,305 shares valued at $462,821. Insiders own 28.10% of the company’s stock.

Institutional Investors Weigh In On GeneDx

Institutional investors have recently modified their holdings of the stock. Thompson Davis & CO. Inc. increased its position in shares of GeneDx by 99.4% during the fourth quarter. Thompson Davis & CO. Inc. now owns 19,944 shares of the company’s stock valued at $55,000 after acquiring an additional 9,944 shares in the last quarter. PFG Investments LLC purchased a new position in shares of GeneDx in the first quarter worth $95,000. Decheng Capital LLC bought a new position in shares of GeneDx during the fourth quarter valued at $285,000. Gagnon Advisors LLC boosted its position in shares of GeneDx by 41.6% during the first quarter. Gagnon Advisors LLC now owns 211,393 shares of the company’s stock valued at $1,930,000 after buying an additional 62,059 shares during the last quarter. Finally, Gagnon Securities LLC increased its holdings in GeneDx by 59.3% in the 1st quarter. Gagnon Securities LLC now owns 556,305 shares of the company’s stock worth $5,079,000 after buying an additional 207,027 shares in the last quarter. 61.72% of the stock is owned by hedge funds and other institutional investors.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.